Cover Image

Complete remission of metastatic HER2+ oesophagogastric junctional adenocarcinoma under long-term trastuzumab treatment

Metastatic gastric cancer (GC) and oesophagogastric junctional (OGJ) adenocarcinoma have a poor clinical outcome with a high worldwide burden of disease. A 65-year old male patient with microcytic anemia was diagnosed with stage IV OGJ adenocarcinoma with multiple liver metastases. Immunohistochemic...

Full description

Saved in:
Bibliographic Details
Main Authors: Gutting, Tobias (Author) , Schulte, Nadine (Author) , Belle, Sebastian (Author) , Betge, Johannes (Author) , Härtel, Nicolai (Author) , Wilke, Jürgen (Author) , Weers, Jürgen (Author) , Ebert, Matthias (Author) , Zhan, Tianzuo (Author)
Format: Article (Journal)
Language:English
Published: 2019
In: Journal of gastrointestinal and liver diseases
Year: 2019, Volume: 28, Issue: 4, Pages: 503-507
ISSN:1842-1121
DOI:10.15403/jgld-397
Online Access:Verlag, Volltext: https://doi.org/10.15403/jgld-397
Verlag: https://www.jgld.ro/jgld/index.php/jgld/article/view/397
Get full text
Author Notes:Tobias Gutting, Nadine Schulte, Sebastian Belle, Johannes Betge, Nicolai Härtel, Jürgen Wilke, Jürgen Weers, Matthias P. Ebert, Tianzuo Zhan
Description
Summary:Metastatic gastric cancer (GC) and oesophagogastric junctional (OGJ) adenocarcinoma have a poor clinical outcome with a high worldwide burden of disease. A 65-year old male patient with microcytic anemia was diagnosed with stage IV OGJ adenocarcinoma with multiple liver metastases. Immunohistochemical analysis revealed a high expression of HER2 (3+). Palliative chemotherapy with FLOT (oxaliplatin, 5-fluorouracil, leucovorin and docetaxel) in combination with trastuzumab was initiated. Due to severe adverse events, the therapy was de-escalated to trastuzumab monotherapy after six months of treatment. Initial restaging revealed partial response after the combination therapy of FLOT with trastuzumab. After reduction to trastuzumab monotherapy, the disease remained stable for two years until radiological complete response was observed. Trastuzumab monotherapy was continued for another two years to maintain complete response. Eleven months after the discontinuation of the therapy, no recurrence of the disease was detected. In conclusion, complete response can be achieved under trastuzumab monotherapy in exceptional responders.
Item Description:Gesehen am 11.02.2020
Physical Description:Online Resource
ISSN:1842-1121
DOI:10.15403/jgld-397

Similar Items